We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.15 | -1.29% | 87.70 | 87.45 | 88.85 | 89.65 | 87.45 | 89.06 | 1,576,217 | 16:40:00 |
From Apr 2019 to Apr 2024
By Adria Calatayud
Shares in C4X Discovery Holdings PLC rose Monday after the company said it has signed a licensing agreement with French pharmaceutical major Sanofi SA to develop a preclinical program as an oral therapy for inflammatory diseases.
C4XD, a London-listed drug-discovery company, said it will receive an upfront payment of 7 million euros ($8.3 million) in addition to potential preclinical milestones of EUR11 million, and clinical and commercial milestones plus royalties. The licensing agreement could be worth up to EUR414 million, the company said.
The agreement is for C4XD's oral IL-17A inhibitor program, the company said. Sanofi will continue to work with the C4XD team as the program advances toward clinical studies, C4XD said.
This is C4XD's second major licensing deal with a global pharmaceutical company, it said.
Shares in C4XD at 0700 GMT were up 28% at 51 pence.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
April 12, 2021 03:19 ET (07:19 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
